January 2010 Volume 7 Number 1
Visit Nature Reviews Clinical Oncology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=36&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to
Nature Reviews Clinical Oncology online. To purchase a subscription, please
visit: http://links.ealert.nature.com/ctt?kn=47&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=71&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 9.113*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
New to NPG this January: Cell Death & Disease
Online. Open access. Author pays.
http://links.ealert.nature.com/ctt?kn=40&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Brought to you by the editorial team of Cell Death & Differentiation, Cell
Death & Disease is a peer-reviewed author-pays online journal that publishes
full-length papers, reviews, and commentaries describing original research in
the field of translational cell death.
Sign up today for Cell Death & Disease's ToC-alert at
http://links.ealert.nature.com/ctt?kn=50&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
=====================================================================
Editorial: Conflict of interest disclosures
Lisa Hutchinson and Vincent T. DeVita Jr
p1 | doi:10.1038/nrclinonc.2009.215
http://links.ealert.nature.com/ctt?kn=25&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Targeted therapies: Pim kinase inhibition and chemoresistance
p3 | doi:10.1038/nrclinonc.2009.198
http://links.ealert.nature.com/ctt?kn=30&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
SRAP-new prognostic marker
p4 | doi:10.1038/nrclinonc.2009.195
http://links.ealert.nature.com/ctt?kn=11&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Hematology: MYC and chemotherapy response
p4 | doi:10.1038/nrclinonc.2009.197
http://links.ealert.nature.com/ctt?kn=15&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Hematology: Early disease predictor for ALL relapse
p5 | doi:10.1038/nrclinonc.2009.193
http://links.ealert.nature.com/ctt?kn=18&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Targeted therapies: Farletuzumab-promising new agent in ovarian cancer
p5 | doi:10.1038/nrclinonc.2009.200
http://links.ealert.nature.com/ctt?kn=87&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Screening: IL-12 polymorphism linked to cervical cancer risk
p6 | doi:10.1038/nrclinonc.2009.194
http://links.ealert.nature.com/ctt?kn=90&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Immunotherapy: EGFRvIII vaccine is safe in GBM
p6 | doi:10.1038/nrclinonc.2009.199
http://links.ealert.nature.com/ctt?kn=79&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Targeted therapies: Sunitinib versus interferon-[alpha] in metastatic RCC
Jason E. Faris and M. Dror Michaelson
p7 | doi:10.1038/nrclinonc.2009.173
Motzer and colleagues present updated results from a multicenter, phase III
trial of sunitinib versus interferon-[alpha] as first-line treatment for
patients with metastatic renal-cell carcinoma. The observed improvement
in overall survival for patients treated with sunitinib further establishes
this agent as the reference standard for first-line treatment of good-risk
and intermediate-risk patients with metastatic renal cancer.
http://links.ealert.nature.com/ctt?kn=82&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Hematology: ATG and Newton's third law of motion
Claudio G. Brunstein
p9 | doi:10.1038/nrclinonc.2009.192
Patients with hematological malignancies have a risk of developing
graft-versus-host disease (GVHD) following allogeneic hematopoietic stem-cell
transplantation. The addition of ATG to prophylaxis regimens decreases the
incidence of GVHD without compromising overall survival in these patients.
http://links.ealert.nature.com/ctt?kn=83&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Surgery: Future directions in multimodality therapy for NSCLC
Anne S. Tsao, Jack A. Roth and Roy S. Herbst
p10 | doi:10.1038/nrclinonc.2009.174
Patients with stage III non-small-cell lung cancer (NSCLC) comprise a
heterogeneous population; the role of surgical resection in this setting
has been controversial. Albain and colleagues recently demonstrated that
trimodality therapy with lobectomy had clinical benefit for patients with
pathologic nodal N2 stage III NSCLC. We discuss the trial and its
implications for future lung cancer therapy.
http://links.ealert.nature.com/ctt?kn=33&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Innovations in the systemic therapy of prostate cancer
Dale R. Shepard and Derek Raghavan
Published online: 08 December 2009
p13 | doi:10.1038/nrclinonc.2009.187
Important innovations have been achieved in the development of novel systemic
hormonal therapies for the salvage treatment of metastatic castrate-resistant
disease. The use of chemotherapy as an adjunct for the treatment of
castrate-resistant metastatic disease and local advanced tumors has also
resulted in patterns of late toxic effects. The authors review the important
advances in the evolution of systemic therapy for the treatment of prostate
cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=62&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=3&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
Philippe L. Bedard, Angelo Di Leo and Martine J. Piccart-Gebhart
Published online: 08 December 2009
p22 | doi:10.1038/nrclinonc.2009.186
Taxanes are among the most widely used chemotherapy agents for breast cancer.
The results of the first-generation taxane trials are reviewed and the
authors discuss the possible explanations for the differences observed
in these studies. The inclusion criteria for future clinical trials of
adjuvant taxane therapy must be revised to account for the molecular
heterogeneity of breast cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=63&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Charged particles in radiation oncology
Marco Durante and Jay S. Loeffler
Published online: 01 December 2009
p37 | doi:10.1038/nrclinonc.2009.183
Radiotherapy is one of the most important and effective therapies used
to treat cancer. Particle therapy is an emerging technique and there is
debate surrounding its cost-effectiveness. The authors of this Review present
clinical results in the field and discuss the research questions that have
arisen with this technique.
Abstract: http://links.ealert.nature.com/ctt?kn=64&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Stereotactic body radiation therapy: a novel treatment modality
Simon S. Lo, Achilles J. Fakiris, Eric L. Chang, Nina A. Mayr, Jian Z. Wang,
Lech Papiez, Bin S. Teh, Ronald C. McGarry, Higinia R. Cardenes and
Robert D. Timmerman
Published online: 08 December 2009
p44 | doi:10.1038/nrclinonc.2009.188
Stereotactic body radiation therapy has emerged as a novel cancer therapy
in the past 10-15 years This review article gives an overview of the
background, radiobiologic, technical and clinical aspects of stereotactic
body radiation therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=65&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=45&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Interaction between capecitabine and brivudin in a patient with breast cancer
Jose M. Baena-Canada, Maria J. Martinez, Obdulia Garcia-Olmedo, Reyes
Jimenez-Barcenas and Pedro Muriel-Cueto
p55 | doi:10.1038/nrclinonc.2009.185
This Case Study describes a patient with breast cancer who was treated
with capecitabine and experienced a severe adverse event when treated with
brivudin for a herpes infection. The authors discuss drug-drug interactions
and management of the associated toxic effects.
Abstract: http://links.ealert.nature.com/ctt?kn=66&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Explanations for worsening cancer survival
Esther de Vries, Henrike E. Karim-Kos, Maryska L. G. Janssen-Heijnen,
Isabelle Soerjomataram, Lambertus A. Kiemeney and Jan Willem W. Coebergh
p60 | doi:10.1038/nrclinonc.2009.184
When cancer survival statistics worsen over time a common assumption is
that care must have deteriorated. A variety of reasons cause cancer survival
to drop, including improved diagnosis of premalignant lesions, deleterious
changes in the distribution of prognostic factors, and changes in the
distribution of sociodemographic characteristics. In this article, the
pitfalls of comparing published population-based survival data from different
time periods or populations are discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=67&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=54&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
British Journal of Cancer presents:
Breast cancer: Improved care through effective management of febrile
neutropenia
An examination of the increasing use of intensive adjuvant regimens for
breast cancer, and the increased rates of febrile neutropenia associated
with these regimens.
http://links.ealert.nature.com/ctt?kn=29&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=70&m=34511017&r=MTc2NDg2OTc4MQS2&b=2&j=NjI5MzMwOTES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
